Chimeric allergen receptor regulatory T cells suppress birch pollen allergic airway inflammation.

Authors

Ana Alcaraz-Serna, Noémie Chillier, Aurélien Trompette, Laura Ermellino, Raphaël Porret, Erica Lana, Rebecca Cecchin, Apiha Shanmuganathan, Seher Guney, Oscar Alfageme-Abello, Eleonora Pace, Antonio Mancarella, Jeremy Campos, Mathilde Foglierini, Christophe von Garnier, Craig Fenwick, Laurent Perez, Niki Ubags, Yannick D Muller

Published in

The Journal of experimental medicine. Volume 223. Issue 8. Aug 03, 2026. Epub Jul 06, 2026.

Abstract

Asthma is a deadly chronic respiratory disease affecting over 300 million people. While allergen immunotherapy remains the only disease-modifying treatment, it is poorly applicable for patients with severe asthma. Here, we explored the therapeutic potential of regulatory T cells (Tregs) armed with chimeric allergen receptors-named CAlleR-redirected against the major allergen of birch pollen Bet v1. Four novel anti-Bet v1 antibodies were identified and used to engineer and functionally validate CAlleR. CAlleR Tregs showed specific in vitro activation and suppression and significantly reduced the airway hyperresponsiveness in birch pollen-sensitized mice. Mechanistically, CAlleR Tregs migrated to the lungs and mediastinal lymph nodes, interacted with CD11c+ dendritic cells, and were activated in a FcγR-dependent manner by cross-presenting Bet v1 stabilized with noncompetitive anti-Bet v1 antibodies. These findings unveil a novel mechanism for targeting soluble antigens and highlight the potential of CAlleR Tregs to prevent and treat severe allergies.

PMID:
42405950
Bibliographic data and abstract were imported from PubMed on 06 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.